Alpha 2.0
Login Register
» Authors » Chris Webber

Chris Webber

Explore the profile of Chris Webber including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 805
Followers 0
Related Specialties
Allergy & Immunology
Infectious Diseases
General Medicine
Top 10 Co-Authors
William C Gruber
Marc J M Bonten
Kathrin U Jansen
Michael W Pride
Beate Schmoele-Thoma
Scott Patterson
John L Perez
Nicholas Kitchin
Daniel A Scott
Susanne M Huijts
Published In
Vaccine
Hum Vaccin Immunother
Clin Infect Dis
Expert Rev Vaccines
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection
Donskey C, Dubberke E, Klein N, Liles E, Szymkowiak K, Wilcox M, et al.
Clin Infect Dis . 2024 Aug; 79(6):1503-1511. PMID: 39180325
Background: Clostridioides difficile infection (CDI) causes substantial mortality and healthcare burden. We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention. Methods: This phase 3 observer-blinded study randomized (1:1)...
2.
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
Cai Y, Diallo S, Rosenthal K, Ren K, Flores D, Dippel A, et al.
Sci Transl Med . 2024 Jun; 16(753):eado2817. PMID: 38924429
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in variants that can escape neutralization by therapeutic antibodies. Here, we describe AZD3152, a SARS-CoV-2-neutralizing monoclonal antibody designed...
3.
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19
Clegg L, Stepanov O, Schmidt H, Tang W, Zhang H, Webber C, et al.
Antimicrob Agents Chemother . 2024 Mar; 68(5):e0158723. PMID: 38534112
AZD7442 is a combination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies, tixagevimab and cilgavimab, developed for pre-exposure prophylaxis (PrEP) and treatment of coronavirus disease 2019 (COVID-19). Using data...
4.
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age
Christensen S, Bouguermouh S, Ilangovan K, Pride M, Webber C, Lockhart S, et al.
Vaccine . 2023 Nov; 41(50):7548-7559. PMID: 37977942
Background: A toxoid-based Clostridioides difficile vaccine is currently in development. Here, we report lot-to-lot consistency, immunogenicity, safety, and tolerability of 3 C difficile vaccine doses in healthy older adults. Methods:...
5.
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years
Remich S, Kitchin N, Peterson J, Li P, Pride M, Brock L, et al.
J Infect Dis . 2023 Aug; 229(2):367-375. PMID: 37531657
Background: This phase 2 extension explored the long-term antibody persistence of an investigational Clostridioides difficile vaccine and the safety, tolerability, and immunogenicity of dose 4 approximately 12 months post-dose 3....
6.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Munoz F, Sher L, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al.
N Engl J Med . 2023 Feb; 388(7):621-634. PMID: 36791162
Background: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children. Methods: We conducted a phase 1 dose-finding study and are conducting an ongoing phase...
7.
A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children
Cutland C, Peyrani P, Webber C, Newton R, Cutler M, Perez J
Vaccine . 2023 Jan; 41(5):1153-1160. PMID: 36621408
Background: Immunogenicity and safety up to 5 years after administration of 1 or 2 doses of quadrivalent meningococcal serogroup A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) given...
8.
Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine
Serra L, Webber C, Burman C, Bueti P, Gorruso M, Mather S
Vaccine . 2022 Oct; 40(49):7014-7021. PMID: 36283896
Background: The meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix®; Pfizer Ltd, Sandwich, Kent, UK) is licensed in more than 80 countries worldwide for the...
9.
Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years
Lawrence J, Kitchin N, Anderson A, Pride M, Jansen K, Gruber W, et al.
Vaccine . 2021 Sep; 39(40):5991-6003. PMID: 34483022
Background: Two phase 1/phase 2 studies assessed 2 formulations of investigational bivalent Clostridioides (Clostridium) difficile vaccine (QS-21 adjuvanted toxoid and toxoid-alone) in healthy adults 50-85 years of age. Methods: The...
10.
Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age
Vesikari T, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, et al.
Hum Vaccin Immunother . 2020 Jun; 16(6):1280-1291. PMID: 32598244
This phase 3B, open-label, extension study (NCT01962207) evaluated long-term persistence of antibodies induced by the quadrivalent meningococcal vaccine conjugated to tetanus toxoid (MenACWY-TT) compared with the meningococcal serogroup C vaccine...